REG - Graft Polymer (UK) - Regulatory Application

Graft Polymer (UK)Announcement

28/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240528:nRSb9341Pa&default-theme=true

RNS Number : 9341P  Graft Polymer (UK) PLC  28 May 2024

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

28 May 2024

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

 

Filing of US Provisional Patent for Substance Use Disorders Treatment

 

Graft Polymer (UK) Plc (LSE: GPL) announces that it has filed a utility patent
application (provisional) with the United States Patent and Trademark Office
(USPTO) for the use of its proprietary and patented self-nanoemulsifying drug
delivery systems (SNEDDS) platform for the delivery of drugs for the treatment
of substance use disorders.

 

 

Patent Filing Overview

The provisional patent application, titled 'Composition and methods for
substance use disorders (SUDS) using a self-nanoemulsifying drug delivery
systems (SNEDDS)', covers the innovative application of Graft Polymer's SNEDDS
platform to enhance the bioavailability, pharmacokinetics, and stability of
therapeutics used in the treatment of substance use disorders many of which
have poor solubility, leading to suboptimal drug delivery and posing an
obstacle to successful formulation. This approach aims to leverage the
Company's existing advanced biopolymer expertise to address significant unmet
medical needs in addiction therapy.

 

 

Strategic Significance

The filing of this patent marks further progress in the Company's strategic
focus on the healthcare industry, following the disposal of its industrial
plastic manufacturing unit, Graft Polymer D.O.O, as announced on 3 May 2024.
This disposal has enabled the Company to focus its attention and resources on
its Graft Bio division, which represents, in the Directors' opinion,  strong
prospectivity through its intellectual property (IP), licensing agreements,
and sales contracts.

 

 

Anthony Tennyson, CEO commented

"We are delighted to announce this progress in leveraging our existing
biopolymer intellectual property for important healthcare applications with
substantial unmet medical needs."

 

 

Enquiries

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director

Email: anthonytennyson@graftpolymer.com

Yifat Steuer, CFO and Executive Director

Email: yifat@graftpolymer.com

 

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner (Corporate Finance)

Guy McDougall (Sales)

 +44 (0) 20 3328 5656

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAPAIMMTMTJTTRI